SpringWorks Therapeutics to Present Progress Across the

-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA’s Real-Time Oncology Review (RTOR) Program, Expected in Second Half...

Related Keywords

Colorado ,United States ,Denver ,Neal Rosen ,Mike Burgess ,Samantha Hilson Sandler ,Enida Haupt ,Qa Saqib Islam ,Jim Cassidy ,Bree Wilky ,L Mary Smith ,Bhavesh Ashar ,Breelyn Wilky ,Saqib Islam ,Badreddin Edris ,Program Update Jim Cassidy ,Therapy Combination Development Mike Burgess ,Linkedin ,Twitter ,Drug Administration ,Nasdaq ,Company Rd Day ,Oncology At Memorial Sloan Kettering Cancer Center ,Combination Development Jim Cassidy ,Inhibitor Program Overview Mike Burgess ,University Of Colorado ,Springworks Therapeutics Inc ,Desmoid Tumors ,Which Will Be Reviewed Under ,Time Oncology Review ,Second Half ,Evaluate Nirogacestat ,Ovarian Granulosa Cell ,Clinical Collaborations Evaluating Nirogacestat ,Therapy Ongoing ,Low Dose ,Additional Sub Studies ,Being Evaluated ,Combination Studies ,Rare Oncology Indications ,Biomarker Defined Solid ,Cohort Expansion ,Execute Across Current Rd Programs ,Serve Patients ,Desmoid Tumors Starting ,Works Therapeutics ,Work Rd Day ,Chief Executive Officer ,Chief Operating Officer ,Chief Development Officer ,Chief Commercial Officer ,Chief Medical ,Sarcoma Medical Oncology ,Mechanism Based Therapy ,Medical Oncology ,Memorial Sloan Kettering Cancer Center ,Business Overview ,Unmet Need ,Tumor Commercial Opportunity ,Expansion Opportunity ,Combination Development ,Expansion Opportunities ,Clinical Data ,Program Update ,Program Overview ,Conference Call Information ,Private Securities Litigation Reform Act ,Springwork Quarterly Report ,Nasdaq Swtx ,Springworks Therapeutics ,Nc ,